摘要
目的:评价电针三阴交、悬钟、非穴对原发性痛经患者是否存在累积镇痛效应及其效应差异。方法:采用随机方法将200例原发性痛经患者分为三阴交组、悬钟组、非穴组、对照组,每组各50例。三阴交组、悬钟组、非穴组于痛经开始发作并且疼痛视觉模拟评分量表(visual analogue scale,VAS)≥40时进行电针治疗,每次30min,每日1次,连续治疗3d。分别在3次治疗前及3次起针即刻(电针30min)测量VAS值,同时分别在上述观察时点记录痛经总体伴随症状严重程度评分(RSS-COX 2总分)。结果:三阴交组、悬钟组、非穴组VAS值的降低程度显著大于对照组(P<0.001),三阴交组、悬钟组、非穴组组间两两比较差异均无统计学意义(P>0.05);三阴交组、悬钟组、非穴组RSS-COX 2总分降低程度显著大于对照组(P<0.05),三阴交组、悬钟组、非穴组组间两两比较差异无统计学意义(P>0.05)。结论:电针三阴交、悬钟、非穴对原发性痛经患者的累积镇痛效应及痛经总体伴随症状严重程度的改善均优于未进行治疗的患者;三阴交、悬钟、非穴三者之间的累积镇痛效应无差异。
Objective To compare the cumulative analgesic effect of electroacupuncture （EA） stimulation of Sanyinjiao （SP 6）, Xuanzhong （GB 39） and non-acupeint for primary dysmenorrhea patients. Methods A total of 200 patients with prima ry dysmenorrhea were randomly assigned to Sanyinjiao （SP 6, a dysmenorrheal-relieving related acupoint） group, Xuanzhong （GB 39, an unrelated acupoint） group, non-acupoint group and control group, with 50 cases in each group. The participants were administered with EA （2 Hz/100 Hz, 0.5- 1.6 mA） at SP 6, GB 39 and non-acupoint for 30 min, once daily for 3 consecutive days. The intensity of the pain was ranked from 0 （no pain） to 100 （intolerable） using visual analogue scale （VAS） and RSS （Cox retrospective symptom scale） severity rating scores （RSS-COX 2） before and after three interventions. Results In comparisonwith the control group, VAS and RSS-COX 2 scores were significantly lower in the SP 36, GB 39 and non-acupoint groups （ P0 001, P〈0.05）, suggesting an alleviation of the pain severity after EA treatment. No significant differences were found a- mong the three treatment groups in both VAS and RSS-COX 2 scores （P〈0.05）. Conclusion EA stimulation of SP 6, GB 39 and non-acupoint has a good cumulative analgesic effect in patients with primary dysmenorrhea.
出处
《针刺研究》
CAS
CSCD
北大核心
2013年第5期393-398,共6页
Acupuncture Research
基金
国家重点基础研究发展计划(2006CB 504503
2012CB 518506)
国家自然科学基金面上项目(30973793)
教育部博士点基金项目(20090013110005)
关键词
原发性痛经
累积镇痛效应
三阴交
悬钟
非穴
多中心随机对照临床试验
Primary dysmenorrhea
Cumulative analgesic effect
Sanyinjiao （SP 6）
Xuanzhong （GB 39）
Non-acupoint
Multicenter randomized controlled clinical trial
